Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) EBITDA (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed EBITDA for 16 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 167.28% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.0 million, a 207.19% increase, with the full-year FY2024 number at -$3.4 million, up 66.38% from a year prior.
  • EBITDA was $2.5 million for Q3 2025 at Xtant Medical Holdings, down from $4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $6.8 million in Q4 2024 to a low of -$3.8 million in Q4 2023.
  • A 5-year average of -$690368.4 and a median of -$1.4 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 285.42% in 2021, then tumbled 36520.0% in 2022.
  • Xtant Medical Holdings' EBITDA stood at $925000.0 in 2021, then crashed by 286.38% to -$1.7 million in 2022, then tumbled by 120.77% to -$3.8 million in 2023, then skyrocketed by 278.06% to $6.8 million in 2024, then plummeted by 62.51% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EBITDA are $2.5 million (Q3 2025), $4.6 million (Q2 2025), and $1.1 million (Q1 2025).